(English)
Chime Biologics Congratulates Hope Medicine Inc. on Successful Dosing of First Patient in Phase III Clinical Trial for Endometriosis in China
March 2026, Shanghai, China — Chime Biologics, a leading global CDMO that enables its partners' success in biologics, congratulates its partner Hope Medicine Inc. on the successful dosing of the first patient in the Phase III clinical trial of HMI-115, a novel monoclonal antibody developed for the treatment of endometriosis. This milestone was achieved at the lead site, Peking Union Medical College Hospital, in China. The trial is a multi-center, randomized, double-blind, placebo-controlled study aimed at evaluating the safety and efficacy of HMI-115 in treating moderate to severe pain associated with endometriosis.
As a key partner in this project, Chime Biologics provided essential process development and GMP manufacturing support for the Phase III clinical trial, ensuring the high quality and stable supply of clinical trial materials. The successful dosing of the first patient marks the official entry of the project into the critical clinical phase, showcasing the outstanding capabilities of both parties in efficient collaboration and project execution.
Empowering China’s Innovative Biopharma to Go Global, Creating New Pathways for Global Development and Manufacturing.
In the face of accelerating competition in the global biopharmaceutical industry, an increasing number of Chinese innovative pharmaceutical companies are turning their attention to international markets. From IND filings to multi-regional clinical development, to global registration and commercialization, achieving higher efficiency and quality in cross-regional advancement has become key to helping companies realize significant value growth.
Chime Biologics continues to deepen its integrated service capabilities to empower "going global." The company has built a CMC development and GMP manufacturing system that meets global regulatory standards, supporting its partners in accelerating clinical projects targeting markets in the U.S., Europe, and beyond. Through forward-thinking process development strategies, robust technology transfer capabilities, and high-quality clinical supply, Chime Biologics will continue to work with global innovative biopharma companies, helping more projects accelerate into clinical trials and move toward commercialization.
Executive Statements
Dr. Sheng Tu, President of Hope Medicine Inc., commented:
“We are very pleased to see HMI-115 smoothly enter Phase III clinical trials in China and successfully dose the first patient. This milestone marks the project’s entry into the critical validation phase, reflecting the efficient collaboration between our team and partners. Chime Biologics has provided high-quality and reliable support in clinical supply, laying a solid foundation for the project’s smooth progress. We will continue to drive innovation with science and accelerate the development of innovative therapies to benefit patients worldwide.”
Dr. Jimmy Wei, CEO of Chime Biologics, stated:
“We warmly congratulate Hope Medicine on reaching this significant milestone with the dosing of the first patient in the Phase III clinical trial. It is Chime Biologics' important responsibility to provide stable and high-quality clinical trial materials at this critical stage for the HMI-115 project. We are committed to helping our partners accelerate clinical progress and reduce development risks through our efficient integrated development and manufacturing platform. Looking ahead, we are excited to deepen our collaboration with Hope Medicine and jointly advance this innovative therapy to benefit patients globally.”
Let me know if you need any adjustments!
About Hope Medicine
Hope Medicine Inc. is a science-driven, patient-centric, clinical-stage biotech company with research and development bases in major innovation hubs in China. The company was established on the foundation of deep understanding of disease biology and translational medicine, and decades of scientific research in the laboratory of the founder, Professor Rui-Ping Xiao, at Peking University. With a management team of highly accomplished industry veterans combining entrepreneurship and global pharma experience, Hope Medicine Inc. is committed to the discovery, development, and commercialization of innovative, safe, effective, affordable medicines for large, underserved patient populations.
About Chime Biologics
Chime Biologics is a leading global CDMO, focused on ensuring our customers' success in delivering innovative biologics as well as biosimilars to patients across the world. Chime Biologics can support customers end to end, from pre-clinical support and cell line development through to clinical and commercial manufacturing of drug substance and drug product. Employing our state-of-the-art capabilities in our Europe Innovation Hub (Basel, CH), China Innovation Hub (Shanghai, CN), Development & Manufacturing Campus (Wuhan, CN) and proven success in supporting our clients with their clinical and commercial authorizations across the globe, Chime Biologics is a true end-to-end solution provider for the biologics industry. With over 600 skilled employees, we share a common goal to make cutting-edge biologics affordable and accessible to patients worldwide, fulfilling our commitment to improving human health globally.
For more information, please visit www.chimebiologics.com.
